Who are TMC-114/RTV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): zidovudine+lamivudine+lopinavir/ritonavir, Atazanavir/Ritonavir + Famotidine, Kaletra + Current Dual NRTI Backbone, Lopinavir and Ritonavir Tablets, Darunavir / Ritonavir + Tenofovir / Emtricitabine, Darunavir/r.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tmc-114-rtv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TMC-114/RTV — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TMC-114/RTV (TMC-114/RTV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor. Area: Infectious diseases.

phase 3 Protease inhibitor HIV protease Infectious diseases Small molecule Live · refreshed every 30 min

Target snapshot

TMC-114/RTV (TMC-114/RTV) — Tibotec Pharmaceuticals, Ireland. TMC-114/RTV is a protease inhibitor used in the treatment of HIV-1 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TMC-114/RTV TARGET	TMC-114/RTV	Tibotec Pharmaceuticals, Ireland	phase 3	Protease inhibitor	HIV protease
zidovudine+lamivudine+lopinavir/ritonavir	zidovudine+lamivudine+lopinavir/ritonavir	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase and HIV protease
Atazanavir/Ritonavir + Famotidine	Atazanavir/Ritonavir + Famotidine	Bristol-Myers Squibb	marketed	HIV protease inhibitor (boosted) + H2-receptor antagonist	HIV protease; CYP3A4 (ritonavir); H2 receptor (famotidine)
Kaletra + Current Dual NRTI Backbone	Kaletra + Current Dual NRTI Backbone	University of Chicago	marketed	Protease inhibitor combination	HIV protease
Lopinavir and Ritonavir Tablets	Lopinavir and Ritonavir Tablets	DualityBio Inc.	marketed	HIV protease inhibitor	HIV protease
Darunavir / Ritonavir + Tenofovir / Emtricitabine	Darunavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Darunavir/r	Darunavir/r	Juan A. Arnaiz	marketed	HIV protease inhibitor	HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor class)

Pfizer · 4 drugs in this class
French National Agency for Research on AIDS and Viral Hepatitis · 4 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class
Christopher J. McLeod · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Janssen R&D Ireland · 1 drug in this class
Janssen-Cilag International NV · 1 drug in this class
Johns Hopkins University · 1 drug in this class
Medical Research Council · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TMC-114/RTV — Competitive Intelligence Brief. https://druglandscape.com/ci/tmc-114-rtv. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing